Cannabis withdrawal is a recognised clinical syndrome in the DSM-5 (code 292.0), defined by the emergence of at least three characteristic symptoms within approximately one week of cessation after prolonged, heavy use. The timeline below covers the typical progression from acute physical symptoms through full neurological recovery.
Why Withdrawal Occurs
THC is highly lipophilic. It is absorbed rapidly into adipose tissue during use and released slowly over days to weeks after cessation. In heavy long-term users, extensive THC stores continue leaching into the bloodstream well after the last dose. CB1 receptors throughout the brain, which were chronically overstimulated by exogenous THC, are suddenly left without their usual agonist input. The resulting receptor vacancy produces measurable physical and psychological symptoms.
CB1 receptor downregulation is the core driver. Chronic THC exposure causes internalisation of CB1 receptors, reducing their surface availability. Restoration of normal receptor density and sensitivity takes weeks to months, not days.
Symptom Timeline
| Phase | Timeframe | Primary Symptoms |
|---|---|---|
| Onset | Days 1–3 | Temperature dysregulation, night sweats, nausea, headaches, tremors, sleep disruption begins |
| Peak physical | Days 3–7 | Severe insomnia (2–4 hours of broken sleep common), vivid dreams from REM rebound, irritability, suppressed appetite, persistent headaches, restless energy with paradoxical exhaustion |
| Emotional trough | Weeks 2–4 | Anhedonia, depressed mood, anxiety, peak cravings (especially in habitual-use contexts), sleep gradually improving to 5–6 hours by week 4 |
| Gradual recovery | Months 2–3 | Memory improvement noticeable around weeks 6–8, processing speed increases, emotional regulation stabilises, low-grade anxiety may persist |
| Full resolution | Months 4–6 | Cognitive function returns to pre-use baseline, emotional stability established, cravings become infrequent and manageable |
Days 1–3: Physical Onset
Symptoms emerge within 24–72 hours of the last dose. Day 3 is typically the worst of the initial physical phase. The autonomic nervous system, which adapted to chronic CB1 activation, produces temperature dysregulation and night sweats. Gastrointestinal discomfort (nausea, reduced appetite) and headaches ranging from dull aches to sharp tension-type pain are common. Tremors and a feeling of internal jitters reflect noradrenergic rebound.
Week 1: Peak Physical Symptoms
This is the most physically demanding phase. Insomnia is often severe - 2 to 4 hours of fragmented sleep per night is a common report in clinical literature. REM sleep, which was suppressed during active cannabis use, rebounds aggressively, producing unusually vivid and often disturbing dreams. Irritability becomes disproportionate to external triggers. Night sweats may soak bedding. Appetite remains suppressed.
The restless-but-exhausted paradox is characteristic: the body feels deeply fatigued while the nervous system is hyperactivated.
Weeks 2–4: The Emotional Low
Physical symptoms gradually ease, but psychological symptoms intensify. This is the phase most cited as the reason for relapse. Anhedonia - the inability to experience pleasure from normally rewarding activities - emerges around the start of week two. This is a direct consequence of the dopamine system recalibrating. CB1 receptors downregulated by chronic THC exposure are slowly returning to normal sensitivity, but the process is incomplete.
Depressed mood and generalised anxiety frequently co-occur. Cravings tend to peak during weeks 2–3, particularly when encountering situations, locations, or social contexts previously associated with use.
Sleep quality improves gradually. By week 4, most individuals report achieving 5–6 hours of consolidated sleep per night, though this remains below typical pre-withdrawal baselines.
Months 2–3: Gradual Return
Cognitive function begins visibly improving around weeks 6–8. Short-term memory, verbal fluency, and processing speed all show measurable gains in this window. Emotional regulation stabilises as neurotransmitter systems reach a new equilibrium. Some individuals continue to experience low-grade anxiety that persists beyond the resolution of other symptoms.
The subjective experience during this phase is often described as "reconnecting" - emotions that were blunted during chronic use become accessible again, which can itself feel disorienting.
Months 4–6: Full Neurological Recovery
By this point, the acute withdrawal syndrome is fully resolved. CB1 receptor density has returned to near-normal levels. Dopamine signalling in the ventral striatum - the primary reward centre - normalises. Cognitive function stabilises at the individual's true baseline, which is often higher than expected after years of impairment.
Occasional cravings may still arise, particularly during stress or exposure to use-related cues, but they are typically brief and manageable.
CB1 Receptor Upregulation
The neurological recovery process centres on CB1 receptor re-sensitisation. PET imaging studies have demonstrated that CB1 receptor availability in chronic cannabis users is significantly reduced compared to controls, and that this availability recovers progressively during abstinence. The timeline for receptor normalisation varies by brain region, with cortical areas recovering faster than subcortical structures.
Dopamine Normalisation
Chronic cannabis use blunts dopamine reactivity in the striatum, as demonstrated by Volkow et al. (2014) using PET imaging with [11C]raclopride. In that study, chronic users showed significantly attenuated dopamine release in response to a methylphenidate challenge compared to controls - 11% vs 25% reduction in the ventral striatum (P = 0.02). Recovery of dopamine reactivity is gradual and may take several months of abstinence.
Factors Affecting the Timeline
Several variables influence the duration and severity of withdrawal:
- Duration of use. Longer use histories are associated with more severe and prolonged withdrawal. Users with histories exceeding a decade consistently report symptoms extending beyond the typical acute window.
- Frequency and dose. Multiple-times-daily use produces the most severe withdrawal. Higher-potency products (concentrates, high-THC strains) create stronger dependence.
- Body composition. Higher body fat percentage extends the elimination half-life of THC and its metabolites, as THC is stored preferentially in adipose tissue.
- Co-occurring ADHD. Individuals with ADHD may experience prolonged and intensified withdrawal symptoms due to pre-existing dysregulation of the dopamine system. The catecholamine deficit characteristic of ADHD compounds the dopamine blunting caused by chronic cannabis use.
- Age of onset. Earlier initiation of cannabis use is associated with more negative emotionality during and after withdrawal (r = 0.58, P = 0.003; Volkow et al., 2014).
Clinical Context
The DSM-5 requires three or more of the following symptoms developing within approximately one week of cessation for a diagnosis of cannabis withdrawal syndrome: irritability or anger, nervousness or anxiety, sleep difficulty, decreased appetite or weight loss, restlessness, depressed mood, and at least one physical symptom (abdominal pain, shakiness/tremors, sweating, fever, chills, headache). The symptoms must cause clinically significant distress or functional impairment.
The anhedonia experienced during weeks 2–4 is not a reflection of underlying personality or pre-existing depression in most cases. It is a transient state caused by the dopamine system recalibrating from chronic overstimulation. CB1 receptors that were downregulated by constant THC exposure are progressively restored, but the process requires patience measured in weeks and months, not days.
References
- American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Cannabis withdrawal syndrome criteria (code 292.0).
- Volkow, N. D., et al. (2014). Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proceedings of the National Academy of Sciences, 111(30), E3149–E3156.
- Fernández-Ruiz, J., et al. (2010). Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neuroscience & Therapeutics, 16(3), e72–e91.
- Budney, A. J., et al. (2004). Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry, 161(11), 1967–1977.